Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Godavari Drugs Ltd. remains a laggard in growth and profitability compared to its peers in the Pharmaceuticals & Drugs industry. While its valuation metrics suggest it is inexpensive, it shows no earnings or revenue growth, making it a high-risk choice. In the current landscape, companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. demonstrate strong financial health and growth potential, standing out as leaders in the sector.
Strong EPS growth (66.76), low PEG (0.35), and solid ROE (16.63%) with competitive margins.
High EPS growth (68.07), low PEG (0.19), and strong profitability metrics (ROE 21.76%).